Cubist Systematic Strategies’s Reata Pharmaceuticals, Inc. Class A Common Stock RETA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q2 | – | Sell |
-34,946
| Closed | -$3.31M | – | 4548 |
|
|
2023
Q1 | $3.18M | Buy |
34,946
+27,627
| +377% | +$1.62M | 0.02% | 1295 |
|
|
2022
Q4 | $278K | Sell |
7,319
-24,065
| -77% | -$828K | ﹤0.01% | 3403 |
|
|
2022
Q3 | $789K | Buy |
31,384
+12,005
| +62% | +$333K | ﹤0.01% | 2819 |
|
|
2022
Q2 | $589K | Sell |
19,379
-8,810
| -31% | -$263K | ﹤0.01% | 2926 |
|
|
2022
Q1 | $923K | Sell |
28,189
-15,432
| -35% | -$458K | 0.01% | 2091 |
|
|
2021
Q4 | $1.15M | Buy |
43,621
+11,886
| +37% | +$920K | 0.01% | 1817 |
|
|
2021
Q3 | $3.19M | Buy |
31,735
+11,713
| +59% | +$1.37M | 0.04% | 719 |
|
|
2021
Q2 | $2.83M | Sell |
20,022
-15,295
| -43% | -$1.73M | 0.03% | 864 |
|
|
2021
Q1 | $3.52M | Buy |
35,317
+22,410
| +174% | +$2.61M | 0.05% | 645 |
|
|
2020
Q4 | $1.6M | Buy |
12,907
+3,004
| +30% | +$395K | 0.02% | 1098 |
|
|
2020
Q3 | $965K | Sell |
9,903
-4,099
| -29% | -$512K | 0.01% | 1357 |
|
|
2020
Q2 | $2.19M | Buy |
14,002
+13,267
| +1,805% | +$2.02M | 0.04% | 729 |
|
|
2020
Q1 | $106K | Sell |
735
-1,448
| -66% | -$280K | ﹤0.01% | 1897 |
|
|
2019
Q4 | $446K | Buy |
2,183
+483
| +28% | +$88.1K | 0.01% | 1613 |
|
|
2019
Q3 | $136K | Buy |
1,700
+1,300
| +325% | +$110K | ﹤0.01% | 1877 |
|
|
2019
Q2 | $38K | Sell |
400
-1,000
| -71% | -$86.3K | ﹤0.01% | 2352 |
|
|
2019
Q1 | $120K | Sell |
1,400
-13,311
| -90% | -$1.1M | ﹤0.01% | 1956 |
|
|
2018
Q4 | $825K | Buy |
14,711
+12,805
| +672% | +$782K | 0.04% | 658 |
|
|
2018
Q3 | $156K | Sell |
1,906
-2,494
| -57% | -$176K | 0.01% | 1486 |
|
|
2018
Q2 | $154K | Buy |
+4,400
| New | +$134K | 0.01% | 1435 |
|
Other funds holding RETA
Cubist Systematic Strategies's RETA Position: Q2 2023 in Review
Cubist Systematic Strategies sold out of Reata Pharmaceuticals, Inc. Class A Common Stock (RETA) in Q2 2023, closing a stake of 34,946 shares — an estimated $3.31M sold.
Cubist Systematic Strategies first reported a position in RETA in Q2 2018 and held it in 20 quarters. The position peaked at $3.52M in Q1 2021. 214 funds tracked by Wall St. Rank hold RETA as of Q2 2023.
- Cubist Systematic Strategies reported no remaining Reata Pharmaceuticals, Inc. Class A Common Stock position as of Q2 2023 after selling out during the quarter.
- Cubist Systematic Strategies sold 34,946 Reata Pharmaceuticals, Inc. Class A Common Stock shares in Q2 2023, an estimated $3.31M.
- Cubist Systematic Strategies first reported a position in Reata Pharmaceuticals, Inc. Class A Common Stock in Q2 2018 and held it in 20 quarters.
- Cubist Systematic Strategies's Reata Pharmaceuticals, Inc. Class A Common Stock position peaked at $3.52M in Q1 2021.
- 214 funds tracked by Wall St. Rank held Reata Pharmaceuticals, Inc. Class A Common Stock as of Q2 2023.
Based on Cubist Systematic Strategies's 13F filing for Q2 2023, filed 14 Aug 2023.